Peptide Reference Guide

Compare mechanisms, clinical evidence and published dose references. Explore individual compounds, common blends and research groupings, with the source and its limitations kept beside each claim.

75 peptides catalogued

Search this library

Search peptides by name, blend, administration type, or category and jump straight to the matching guide.

75 indexed

Browse by Function

Anti-Aging / Aesthetic

12 peptides

BPC-157, Epithalon, FOXO4-DRI, GHK-Cu, Glow, Glutathione, Humanin, Melanotan I, Melanotan II, NAD+, SNAP-8, TB-500

Antioxidant / Immunomodulator

11 peptides

Bronchogen, Cardiogen, Crystagen, Glutathione, KPV, LL-37, Pancragen, TB-500, Thymosin Alpha-1, VIP, Vilon

Energy

11 peptides

5-Amino-1MQ, BAM15, Bam-15, Humanin, MOTS-C, NAD+, SLU-PP-332, SLU-PP-332 + 5-Amino, SLU-PP-332 + BAM15, SLU-PP-332 + Bam-15, SS-31

GLP-1 Weight Loss

10 peptides

Cagri/Sema, Mazdutide, Orforglipron, Retatrutide, SLU-PP-332 + Orforglipron, Semaglutide, Survodutide, Tirzepatide, Zenagamtide, Pemvidutide

Hormonal / Sexual Function

6 peptides

Gonadorelin, HCG, Kisspeptin, Oxytocin, PT-141, Prostamax

Injury Recovery

9 peptides

ARA-290, BPC-157, BPC-157 + TB-500, BPC-157 + TB-500 10mg Blend, Cartalax, GHK-Cu, Klow, TB-500, Wolverine Blend

CJC No DAC / Ipamorelin 10mg, CJC No DAC / Ipamorelin 5mg, CJC-1295, Follistatin-344, GHRP-2, GHRP-6, Hexarelin, IGF-1 LR3, Ipamorelin, Ipamorelin + CJC No DAC 10/10mg, Ipamorelin + CJC No DAC 5/5mg, MK-677, PEG-MGF, Sermorelin, Tesamorelin

Non-GLP-1 Weight Loss

14 peptides

5-Amino-1MQ, AOD-9604, Adipotide, Cagrilintide, Lemon, Lipo-C, MOTS-C, Oxytocin, SLU-PP-332, SLU-PP-332 + 5-Amino, SLU-PP-332 + Orforglipron, Tesamorelin, Tesofensine, Petrelintide

Nootropics / Cognitive Support

10 peptides

DSIP, Dihexa, Dihexa / Methylene Blue / Tesofensine, Epithalon, Glutathione, Methylene Blue, NAD+, Pinealon, Selank, Semax

Common Blends

BPC-157 + TB-500

Evidence-based BPC-157 + TB-500 blend guide covering identity, common 5/5 and 10/10 vial ratios, public dosing-site claims, component evidence limits, and source-tracking risks.

CJC No DAC / Ipamorelin

CJC no DAC plus ipamorelin guide explaining Modified GRF(1-29), why DAC CJC-1295 trial schedules do not transfer, why 5 mg and 10 mg vial totals differ from per-component doses, and how popular dose calculators differ from clinical evidence.

Cagri/Sema

Cagri/Sema blend guide covering CagriSema trial doses, online blend protocols, FDA status, fixed-ratio limits and evidence boundaries as of September 2026.

Dihexa / Methylene Blue / Tesofensine

Current guide for the Dihexa, methylene blue and tesofensine stack, separating public capsule listings from human evidence and highlighting methylene-blue MAOI plus tesofensine serotonin-risk logic.

Glow

Current GLOW blend guide covering the common 50/10/10 vial, fixed 5:1:1 ratio math, GHK-Cu route evidence, BPC-157 and TB-500 limits, public dosing claims, and source-tracking risks.

Klow

Current KLOW guide covering the common 80 mg 50/10/10/10 vial, KPV addition, GLOW-style ratio math, public dosing claims, component evidence limits, and four-way source-tracking risks.

Lemon

Lemon Bottle ingredients, Swissmedic safety findings, disputed product identity and public dose claims, with clear distinctions from approved fat-dissolving medicines.

Lipo-C

Source-checked Lipo-C guide separating MIC, L-carnitine and B12 component evidence, variable compounded formulations, public dose-page claims, and labeled nutrient-injection context.

SLU-PP-332 + 5-Amino

Source-checked guide for the SLU-PP-332 plus 5-Amino-1MQ blend, separating preclinical component evidence, public oral-capsule claims, dosing ambiguity, and the absence of studied combination data.

SLU-PP-332 + BAM15

Evidence-focused SLU-PP-332 plus BAM15 blend guide covering component mechanisms, mouse-only evidence, reported fixed-ratio product amounts, and the absence of a validated human combined protocol.

SLU-PP-332 + Orforglipron

Source-checked guide for the SLU-PP-332 plus orforglipron blend, separating Foundayo label evidence, SLU-PP-332 preclinical data, public stack claims, and the absence of fixed-combination trials.

Wolverine Blend

Conservative Wolverine Blend guide explaining the BPC-157 + TB-500 nickname, common 1:1 vial ratios, TB-500 fragment versus thymosin beta-4 confusion, public dosing claims, and source-tracking risks.